RAZAXABAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H20F4N8O2
Molecular Weight	528.4616
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CC1=NC=CN1C2=CC(F)=C(NC(=O)C3=CC(=NN3C4=CC5=C(ON=C5N)C=C4)C(F)(F)F)C=C2

InChI

InChIKey=OFJRNBWSFXEHSA-UHFFFAOYSA-N

InChI=1S/C24H20F4N8O2/c1-34(2)12-21-30-7-8-35(21)13-3-5-17(16(25)10-13)31-23(37)18-11-20(24(26,27)28)32-36(18)14-4-6-19-15(9-14)22(29)33-38-19/h3-11H,12H2,1-2H3,(H2,29,33)(H,31,37)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17984286 | http://williams.medicine.wisc.edu/new_oral_anticoagulants_2011.pdf | https://www.ncbi.nlm.nih.gov/pubmed/15771420

Razaxaban (also known as BMS-561389 or DPC 906) is an oral factor Xa inhibitor that was being developed for the treatment of thrombosis. It showed excellent results in the lab for efficacy and bioavailability and was therefore selected for further development. In a phase 1 clinical trial with healthy subjects, Razaxaban was well tolerated with minor bleeding. However, higher bleeding was reported in thrombosis patients in a phase 2 clinical trial, and the development of this drug was therefore discontinued in 2005.

Originator

Approval Year

Name

Type

Language

RAZAXABAN

Official Name

English

razaxaban [INN]

Preferred Name

English

1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-N-(4-(2-((DIMETHYLAMINO)METHYL)-1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE

Systematic Name

English

1H-PYRAZOLE-5-CARBOXAMIDE, 1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-N-(4-(2-((DIMETHYLAMINO)METHYL)-1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C263